Literature DB >> 16470360

[Therapy of hypercalcemia with ibandronate in case of acute renal failure].

R Bergner1, D M Henrich, M Hoffmann, D Bruckner, M Uppenkamp.   

Abstract

Hypercalcaemia is a common complication of malignancies associated with bone destruction. Besides, benign diseases as sarcoidosis or hyperparathyroidism may lead to hypercalcaemia. The main principles of modern therapy contain a forced diuresis as well as the application of bisphosphonates. Latter substances bear the danger of developing a renal insufficiency. Here, we report the case of a female patient, suffering from primary hyperparathyroidism with severe hypercalcaemia and calcium levels up to 6 mmol/l, who developed acute renal failure. We treated the patient with forced diuresis and repeated infusions of ibandronate (5 x 6 mg ibandronate). Even if lowering the serum levels of calcium only for a short time after each application, yet we could improve renal function by these means. Only after performing a parathyroidectomy, we could see a sustained decline of calcium levels. This case report supports the results of other publications, that have reported the missing nephrotoxic effect of ibandronate compared to other bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470360     DOI: 10.1007/s00108-005-1547-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  2 in total

1.  Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.

Authors:  Z Geng; M C Monier-Faugere; F Bauss; H H Malluche
Journal:  Clin Nephrol       Date:  2000-07       Impact factor: 0.975

2.  Renal failure with the use of zoledronic acid.

Authors:  Jennie T Chang; Lanh Green; Julie Beitz
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.